LC
DNTH icon

Lindbrook Capital’s Dianthus Therapeutics DNTH Stock Holding History

Lindbrook Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21
Closed -$458 – 2820
2024
Q4 		$458 Buy
21
+4
+24% +$103 ﹤0.01% 2644
2024
Q3 		$465 Buy
+17
New +$474 ﹤0.01% 2687
2020
Q4 		– Sell
-20
Closed -$2K – 1797
2020
Q3 		$2K Buy
+20
New +$2.37K ﹤0.01% 1378
2020
Q1 		– Sell
-94
Closed -$23K – 1714
2019
Q4 		$23K Buy
+94
New +$17.6K 0.01% 682

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lindbrook Capital's DNTH Position: Q1 2025 in Review

Lindbrook Capital sold out of Dianthus Therapeutics (DNTH) in Q1 2025, closing a stake of 21 shares — an estimated $458 sold.

Lindbrook Capital first reported a position in DNTH in Q4 2019 and held it in 4 quarters. The position peaked at $23K in Q4 2019. 98 funds tracked by Wall St. Rank hold DNTH as of Q1 2025.

  • Lindbrook Capital reported no remaining Dianthus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 21 Dianthus Therapeutics shares in Q1 2025, an estimated $458.
  • Lindbrook Capital first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 4 quarters.
  • Lindbrook Capital's Dianthus Therapeutics position peaked at $23K in Q4 2019.
  • 98 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.